Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 2
1989 3
1990 7
1991 4
1992 4
1993 3
1994 4
1995 5
1996 1
1997 3
1998 3
1999 4
2000 3
2001 5
2002 5
2003 4
2004 3
2005 8
2006 8
2007 8
2008 15
2009 14
2010 14
2011 11
2012 7
2013 13
2014 22
2015 20
2016 18
2017 15
2018 19
2019 19
2020 32
2021 14
2022 1
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

284 results
Results by year
Filters applied: . Clear all
Page 1
Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline.
Tuccori M, Ferraro S, Convertino I, Cappello E, Valdiserra G, Blandizzi C, Maggi F, Focosi D. Tuccori M, et al. Among authors: blandizzi c. MAbs. 2020 Jan-Dec;12(1):1854149. doi: 10.1080/19420862.2020.1854149. MAbs. 2020. PMID: 33319649 Free PMC article.
Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression.
Scarpignato C, Gatta L, Zullo A, Blandizzi C; SIF-AIGO-FIMMG Group; Italian Society of Pharmacology, the Italian Association of Hospital Gastroenterologists, and the Italian Federation of General Practitioners. Scarpignato C, et al. Among authors: blandizzi c. BMC Med. 2016 Nov 9;14(1):179. doi: 10.1186/s12916-016-0718-z. BMC Med. 2016. PMID: 27825371 Free PMC article. Review.
Enteric α-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson's disease before brain pathology.
Pellegrini C, D'Antongiovanni V, Miraglia F, Rota L, Benvenuti L, Di Salvo C, Testa G, Capsoni S, Carta G, Antonioli L, Cattaneo A, Blandizzi C, Colla E, Fornai M. Pellegrini C, et al. Among authors: blandizzi c. NPJ Parkinsons Dis. 2022 Jan 12;8(1):9. doi: 10.1038/s41531-021-00263-x. NPJ Parkinsons Dis. 2022. PMID: 35022395 Free PMC article.
P2X4 receptors, immunity, and sepsis.
Antonioli L, Blandizzi C, Fornai M, Pacher P, Lee HT, Haskó G. Antonioli L, et al. Among authors: blandizzi c. Curr Opin Pharmacol. 2019 Aug;47:65-74. doi: 10.1016/j.coph.2019.02.011. Epub 2019 Mar 25. Curr Opin Pharmacol. 2019. PMID: 30921560 Free PMC article. Review.
Editorial: IBD Management-Novel Targets and Therapeutic Perspectives.
Antonioli L, Fornai M, Romano B, Pellegrini C, Blandizzi C. Antonioli L, et al. Among authors: blandizzi c. Front Pharmacol. 2020 Apr 21;11:448. doi: 10.3389/fphar.2020.00448. eCollection 2020. Front Pharmacol. 2020. PMID: 32372955 Free PMC article. No abstract available.
Adenosine Signaling in the Tumor Microenvironment.
Antonioli L, Fornai M, Pellegrini C, D'Antongiovanni V, Turiello R, Morello S, Haskó G, Blandizzi C. Antonioli L, et al. Among authors: blandizzi c. Adv Exp Med Biol. 2021;1270:145-167. doi: 10.1007/978-3-030-47189-7_9. Adv Exp Med Biol. 2021. PMID: 33123998
Microvascular Endothelial Dysfunction in Patients with Obesity.
Virdis A, Masi S, Colucci R, Chiriacò M, Uliana M, Puxeddu I, Bernardini N, Blandizzi C, Taddei S. Virdis A, et al. Among authors: blandizzi c. Curr Hypertens Rep. 2019 Apr 4;21(4):32. doi: 10.1007/s11906-019-0930-2. Curr Hypertens Rep. 2019. PMID: 30949772 Review.
Risankizumab for the treatment of moderate to severe psoriasis.
Chiricozzi A, Antonioli L, Panduri S, Fornai M, Romanelli M, Blandizzi C. Chiricozzi A, et al. Among authors: blandizzi c. Expert Opin Biol Ther. 2019 Jan;19(1):1-8. doi: 10.1080/14712598.2019.1551354. Epub 2018 Nov 27. Expert Opin Biol Ther. 2019. PMID: 30462554 Review.
284 results